Monitoring and Management of Suicidality in Patients Taking Lamotrigine

Baseline Risk Assessment

Patients with bipolar disorder have 8.66 times higher likelihood of dying by suicide compared to the general population, with a lifetime suicide attempt prevalence of 29.2% 2, 3
Major depression carries 8.62 times higher risk of death by suicide, with women facing 9.40 times higher odds 5

The American College of Cardiology is not applicable here, however, patients taking lamotrigine require weekly monitoring for suicidality within 1-2 weeks of initiation or dose changes, with the highest risk period being the first year of treatment, particularly following any hospitalization 1

Assess patient status within 1-2 weeks of starting lamotrigine or any dose change, and document medication adherence, duration of current depressive episode, and social support availability at each visit 1, 6
Continue monitoring throughout the treatment period, as clinical guidelines suggest longer periods of surveillance following discharge 5
Implement caring communications, which reduces suicide attempts by 43% 1

Do not increase the dose of the medication associated with worsening symptoms, and consider adding cognitive behavioral therapy focused on suicide prevention, which demonstrates the strongest evidence for reducing suicide attempts 1, 6
Add a second-generation antidepressant based on adverse effect profiles if depression worsens, and for rapid relief in severe cases, ketamine infusion shows improvement of suicidal ideation within 24 hours under appropriate supervision 1, 6
Assess for hospitalization if there is imminent risk 6

Continue antidepressant treatment for 4-9 months after achieving satisfactory response in first-episode major depression, and for patients with two or more depressive episodes, extend treatment beyond 9 months 1

Patients under age 25 on SSRIs have increased suicide attempts compared to placebo, and women with major depression require particularly close monitoring given their 9.40 times elevated risk 1
Patients with comorbid anxiety disorders or substance use disorders face additional risk, and those with early age of onset, family history, psychotic symptoms, or treatment resistance require intensified surveillance 2, 3